PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Interferon and Cytokine Research

• Publication date

  2010-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/jir.2010.0092PMID 20836711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C

  2012cited by this paper
• Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

  2010cited by this paper
• CSS1-2 Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studiesPharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical

  2009cited by this paper
• T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β

  2009cited by this paper
• The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.

  2008cited by this paper
• [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].

  2008cited by this paper
• Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.

  2008cited by this paper
• IFN‐α regulates Toll‐like receptor‐mediated IL‐27 gene expression in human macrophages

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Peginterferon Alfa-2b plus Ribavirin compared with Interferon Alfa-2b plus Ribavirin for Treatment of Chronic Hepatitis C in HIV Co-infected Hispanic Patients

  2007cited by this paper
• IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages.

  2007cited by this paper
• IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

  2006cited by this paper
• N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

  2006cited by this paper
• Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

  2006cited by this paper
• Immunogenicity of interferon beta: differences among products

  2004cited by this paper
• Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis

  2004cited by this paper
• Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys

  2004cited by this paper
• Biologic role of interferon beta in multiple sclerosis

  2004cited by this paper
• The Interleukin (IL)‐2 Family Cytokines: Survival and Proliferation Signaling Pathways in T Lymphocytes

  2004cited by this paper
• Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.

  2004cited by this paper
• Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system.

  2004cited by this paper
• Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.

  2004cited by this paper
• Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis

  2004cited by this paper
• Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.

  2004cited by this paper
• Effects of interferon-β on microglial functions as inflammatory and antigen presenting cells in the central nervous system

  2004cited by this paper
• Decreased integrin gene expression in patients with MS responding to interferon-beta treatment.

  2004cited by this paper
• What do we know about the mechanism of action of disease-modifying treatments in MS?

  2004cited by this paper
• The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta.

  2003cited by this paper
• Timing of IFN-β Exposure during Human Dendritic Cell Maturation and Naive Th Cell Stimulation Has Contrasting Effects on Th1 Subset Generation: A Role for IFN-β-Mediated Regulation of IL-12 Family Cytokines and IL-18 in Naive Th Cell Differentiation1

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.

  2003cited by this paper
• Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

  2002cited by this paper
• Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells.

  2002cited by this paper
• Differential mechanisms of action of interferon-β and glatiramer acetate in MS

  2002cited by this paper
• Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

  2002cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Interferon-Beta in the Treatment of Multiple Sclerosis

  2001cited by this paper
• Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis.

  2001cited by this paper
• Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.

  2001cited by this paper
• Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b

  2001cited by this paper
• Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis

  2001cited by this paper
• IFN-β1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms

  2001cited by this paper
• Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis

  2001cited by this paper
• Immunomodulatory effects of interferon beta-1a in multiple sclerosis.

  2001cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

  2001cited by this paper
• Structural and biologic characterization of pegylated recombinant IFN-alpha2b.

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.

  2000cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.

  1999cited by this paper
• Characterization of a soluble ternary complex formed between human interferon‐β‐1a and its receptor chains

  1999cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

  1999cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

  1998cited by this paper
• Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β)

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

  1998cited by this paper
• Differences in Activity between α and β Type I Interferons Explored by Mutational Analysis*

  1998cited by this paper
• Interferon beta in the treatment of multiple sclerosis

  1998cited by this paper
• Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

  1998cited by this paper
• Interferon‐β Is a Potent Promoter of Nerve Growth Factor Production by Astrocytes

  1997cited by this paper
• Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling

  1997cited by this paper
• Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

  1997cited by this paper
• Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases.

  1996cited by this paper
• Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells implications for multiple sclerosis and other autoimmune diseases

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Direct Association of STAT3 with the IFNAR-1 Chain of the Human Type I Interferon Receptor (*)

  1996cited by this paper
• Actions of cytokines on the immune response and viral interactions: An overview

  1996cited by this paper
• Treatment of Multiple Sclerosis with Type I Interferons

  1996cited by this paper
• Interferons: biochemistry and mechanisms of action.

  1995cited by this paper
• Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients

  1995cited by this paper
• Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes.

  1995cited by this paper
• Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients.

  1995cited by this paper
• Alpha/beta interferon is a neuronal growth factor.

  1995cited by this paper
• Interferon-β downregulates interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells

  1995cited by this paper
• Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes

  1995cited by this paper
• Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells.

  1995cited by this paper
• Alpha and beta interferons and their receptor and their friends and relations.

  1995cited by this paper
• α and α Interferons and Their Receptor and Their Friends and Relations

  1995cited by this paper
• Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48- kD DNA-binding protein, ISGF3-gamma

  1995cited by this paper
• Ligand-induced association of the type I interferon receptor components

  1995cited by this paper
• The human interferon alpha/beta receptor: characterization and molecular cloning.

  1994cited by this paper
• The human interferon-αgb receptor: Characterization and molecular cloning

  1994cited by this paper
• p135tyk2, an interferon-alpha-activated tyrosine kinase, is physically associated with an interferon-alpha receptor.

  1994cited by this paper
• Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase

  1994cited by this paper
• Clinical trials of interferons in multiple sclerosis. What have we learned?

  1993influential reference
• Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

  1993cited by this paper
• Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• In vitro and in vivo inhibition of mitogen‐driven T‐cell activation by recombinant interferon beta

  1993cited by this paper
• Interferon β decreases T cell activation and interferon γ production in multiple sclerosis

  1993cited by this paper
• Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

  1993cited by this paper
• A protein tyrosine kinase in the interferon alpha/beta signaling pathway.

  1992cited by this paper
• The interferon system. A bird's eye view of its biochemistry.

  1992cited by this paper

• Experience with the use of sampeginterferon beta-1a in real clinical practice in the Moscow region

  2025cites this paper
• Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic.

  2023cites this paper
• Darren P. Baker, PhD A Pioneer in the Development of Pegylated Interferon-β for Clinical Use

  2023cites this paper
• Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.

  2022cites this paper
• Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients – Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting – Results from the Non-Interventional Study PERFECT

  2021cites this paper
• Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study

  2021cites this paper
• Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management

  2021cites this paper
• Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis

  2021cites this paper
• An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

  2019cites this paper
• Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

  2018cites this paper
• Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

  2017cites this paper
• Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

  2017influential citation
• Update on disease-modifying therapies for multiple sclerosis

  2017cites this paper
• Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study

  2017cites this paper
• Thérapeutiques et prise en charge de la sclérose en plaques

  2017cites this paper
• Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients

  2016cites this paper
• Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

  2016cites this paper
• Future of multiple sclerosis therapy in children and adolescents

  2016cites this paper
• Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

  2015influential citation
• Pegyliertes Interferon-beta 1a

  2015cites this paper
• Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation

  2015cites this paper
• PEGylated IFNβ-1a in the treatment of multiple sclerosis

  2015cites this paper
• PEGylated IFNb-1a in the treatment of multiple sclerosis

  2015cites this paper
• Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU

  2015cites this paper
• Przyszłość terapii stwardnienia rozsianego u dzieci i młodzieży

  2015cites this paper
• Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU

  2015cites this paper
• Pegylated Interferons: A Nurses’ Review of a Novel Multiple Sclerosis Therapy

  2014cites this paper
• Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

  2014cites this paper
• Optimization of a high-throughput whole blood expression profiling methodology and its application to assess the pharmacodynamics of interferon (IFN) beta-1a or polyethylene glycol-conjugated IFN beta-1a in healthy clinical trial subjects

  2013cites this paper
• Formulation Approaches and Strategies for PEGylated Biotherapeutics

  2013cites this paper
• PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery.

  2012cites this paper
• Les traitements de première ligne dans la sclérose en plaques

  2012cites this paper
• PEGylation of Interferon-β-1a

  2012cites this paper
• A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

  2012cites this paper
• Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.

  2012cites this paper
• In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a

  2011cites this paper
• Beta-interferon for multiple sclerosis.

  2011cites this paper
• Principles of a new treatment algorithm in multiple sclerosis

  2011cites this paper
• Treatment of multiple sclerosis: current concepts and future perspectives

  2011cites this paper
• Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice

  2011cites this paper